JPMorgan Upgrades Acceleron To Overweight Ahead Of Luspatercept Data
February 26, 2018 at 09:07 AM EST
JPMorgan analyst Eric Joseph upgraded Acceleron Pharma to Overweight from Neutral and raised his price target for the shares to $52 from $33 ahead of pivotal data for lead asset luspatercept in myelodysplastic syndrome and beta-thalassemia.